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Abstract
Background: Smokers have been shown to have lower mortality after acute coronary syndrome than non-
smokers. This has been attributed to the younger age, lower co-morbidity, more aggressive treatment and lower
risk profile of the smoker. Some studies, however, have used multivariate analyses to show a residual survival
benefit for smokers; that is, the “smoker’s paradox”. The aim of this study was, therefore, to perform a systematic
review of the literature and evidence surrounding the existence of the “smoker’s paradox”.
Methods: Relevant studies published by September 2010 were identified through literature searches using EMBASE
(from 1980), MEDLINE (from 1963) and the Cochrane Central Register of Controlled Trials, with a combination of
text words and subject headings used. English-language original articles were included if they presented data on
hospitalised patients with defined acute coronary syndrome, reported at least in-hospital mortality, had a clear
definition of smoking status (including ex-smokers), presented crude and adjusted mortality data with effect
estimates, and had a study sample of > 100 smokers and > 100 non-smokers. Two investigators independently
reviewed all titles and abstracts in order to identify potentially relevant articles, with any discrepancies resolved by
repeated review and discussion.
Results: A total of 978 citations were identified, with 18 citations from 17 studies included thereafter. Six studies
(one observational study, three registries and two randomised controlled trials on thrombolytic treatment)
observed a “smoker’s paradox”. Between the 1980s and 1990s these studies enrolled patients with acute myocardial
infarction (AMI) according to criteria similar to the World Health Organisation criteria from 1979. Among the
remaining 11 studies not supporting the existence of the paradox, five studies represented patients undergoing
contemporary management.
Conclusion: The “smoker’s paradox” was observed in some studies of AMI patients in the pre-thrombolytic and
thrombolytic era, whereas no studies of a contemporary population with acute coronary syndrome have found
evidence for such a paradox.
Background
The term “smoker’s paradox” was introduced into scien-
tific discourse more than 25 years ago following obser-
vations that smokers (in comparison to non-smokers)
experience decreased mortality following an acute myo-
cardial infarction (AMI) [1-4]. Braunwald’s recent text-
book on heart disease argues that the observation that
smoking predicts better outcome following various
reperfusion strategies is not because of any benefit from
smoking but simply because smokers are likely to
undergo such procedures at a much younger age and
hence have on average lower comorbidity [5].
In a recent study we observed a 41% reduction in one-
year mortality in unselected AMI patients following the
switch from a conservative approach in 2003 to the
introduction of routine early invasive management in
2006 [6]. In a sub-analysis of patients with non-ST-seg-
ment elevation myocardial infarction (NSTEMI) this
treatment effect was especially pronounced for smokers.
Current smoking was an independent predictor for one-
year mortality in the 2003 cohort, but not in the 2006
cohort [7]. These observations motivated us to perform
a systematic review of the literature (observational stu-
dies and randomised trials) surrounding the “smoker’s
* Correspondence: erlend.aune@siv.no
1Department of Cardiology, Vestfold Hospital Trust, Tønsberg, Norway
Full list of author information is available at the end of the article
Aune et al. BMC Medicine 2011, 9:97
http://www.biomedcentral.com/1741-7015/9/97
© 2011 Aune et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.paradox” in order to explore possible differences
between study populations with or without this
phenomenon.
Methods
Literature search and study selection
We searched three electronic databases: EMBASE (from
1980 onward), MEDLINE (from 1963 onward) and the
Cochrane Register of Controlled Trials. Our search
strategy combined text words and subject headings iden-
tifying reports relating to acute coronary syndrome/
AMI, smoking status and mortality. The search included
literature published by 22 September 2010. Due to the
long time spans of the databases we decided to perform
two slightly different searches in MEDLINE and
EMBASE, one from 1963/1980 to 1995, the other from
1996 to date of search. (See Additional file 1 for the full
search strategy.) The reference lists of identified studies
were also scanned to identify any other relevant studies,
with the search strategy expanding accordingly.
The original observations of the “smoker’sp a r a d o x ”
was made in patients with an AMI diagnosed according
to the World Health Organisation (WHO) criteria from
1979 [8]. With the introduction for new diagnostic cri-
teria of AMI in 2000 [9] and 2007 [10] in mind, we
chose to extend the search to include patients with ST-
segment elevation myocardial infarction (STEMI) and
non-ST-segment elevation acute coronary syndrome
(NSTEMI and unstable angina pectoris [UAP]).
Two investigators (EA and JEO) independently
reviewed all titles and abstracts to identify potentially
relevant articles and resolved discrepancies by repeated
review and discussion. If two or more studies presented
the same data from a single patient population, we
included these data only once in the review.
No review protocol was used, but we prospectively
defined the following criteria for the inclusion of studies
into our review:
￿ Studies of patients hospitalised for acute coronary
syndrome (ACS), including the previous WHO cri-
teria for AMI [8] and the more recent definition of
ACS, including STEMI, NSTEMI and UAP [9].
￿ The publication should provide a clear definition
of smoking status into current, former and never-
smokers, including baseline characteristics of each
group with age as a minimum. In case former smo-
kers were not defined separately, a minimum requi-
site was that they had to be defined and
characterised either as smokers, non-smokers or per
definition were excluded from the analysis.
￿ Both crude and adjusted total mortality rates should
be presented. Effect estimates should be provided,
and “age” was a minimum requirement as a covariate.
￿ The length of follow-up should be reported and
include at least hospital mortality. Studies reporting
only post-discharge mortality were excluded.
￿ Only English-language original articles were
included.
￿ The study should include > 100 smokers and > 100
non-smokers.
Our own study exploring one-year mortality among
smokers vs. non-smokers with NSTEMI was published
after the literature search was finalised, but the results
were known to us by September 2010, and the study
has therefore been included in this review [7].
Results
The study selection process is presented in Figure 1. In
total, 978 unique citations were identified. Based upon
titles and abstracts, 903 citations could be excluded.
Accordingly, 75 full-length original articles were consid-
ered in depth for inclusion, with 18 publications from
17 studies (7 randomised trials and 10 observational stu-
dies/registries) meeting all inclusion criteria [7,11-27].
The Superior Yield of the New strategy of Enoxaparin,
Revascularization and GlYcoprotein IIb/IIIa inhibitors
(SYNERGY) trial is presented by two publications, one
demonstrating crude mortality rates [22] and another
adjusted mortality rates [24]. The studies were published
between 1991 and 2009 and enrolled patients from 1982
through till 2007. Five studies [7,14,16,19,22,24] were
considered to represent a contemporary population of
ACS and mainly included patients according to the
diagnostic criteria from 2000 [9]. The other studies were
based upon patients included according to the WHO
criteria [8] in the 1980s and 1990s.
The follow-up time in the 17 included studies varied
from in-hospital to three years. Out of six studies with
in-hospital follow-up, two registries demonstrated a
“smoker’sp a r a d o x ”. Four out of six studies with follow-
up between one month and six months found evidence
for the paradox, whereas none of the five studies that
followed patients for one year or more did so.
Study categories and adjusted mortality rates
Study characteristics, with crude and adjusted mortality
rates expressed as odds ratios and hazard ratios and
relative risks with 95% confidence intervals according to
smoking status, are presented in Table 1. The studies
have been sub-divided into six categories according to
study design. The effect estimates for adjusted mortality
rates are presented in Figure 2.
Randomised controlled trials (RCT) in patients treated with
fibrinolysis for STEMI
Both the International TissueP l a s m i n o g e nA c t i v a t o r /
Streptokinase Mortality Trial [12] and the Global
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Activator for Occluded Coronary Arteries (GUSTO-I)
trial [13] demonstrated higher adjusted mortality rates
among non-smokers, that is, supporting a smoker’s
paradox. For the latter study, no such effect was
observed in the angiographic substudy of 2,437 patients.
The Gruppo Italiano per lo Studio della Sopravvivenza
nell’Infarcto Micardico (GISSI-2) trial [23] included
patients with the same factorial study design as the
international study [12], but did not demonstrate any
reduced adjusted in-hospital mortality for smokers com-
pared with never-smokers.
RCT in STEMI treated with percutaneous coronary
intervention (PCI)
In the Controlled Abciximab and Device Investigation to
Lower Late Angioplasty Complications (CADILLAC)
trial 2,082 patients with STEMI undergoing primary PCI
were randomised to either angioplasty or stenting with
Citations identified through 
database searching
(n = 1608)
Additional citations identified 
through other sources
(n = 1)
Citations after duplicates removed
(n = 978)
Citations screened
(n = 978)
Citations excluded based upon titles and 
abstracts
(n = 903)
Full-text articles 
assessed for eligibility
(n = 75)
Full-text articles excluded
( n = 57)
Reasons:
Total mortality in relation to smoking status 
not presented n = 29
Non-ACS study n = 9
Small study (<100 smokers or <100 non-
smokers) n = 4
Editorial n = 1
Letter to editor n = 1
No adjusted survival analysis n = 7
No effect estimates reported n = 1
Unclear smoking status definition n = 3
Smoking cessation study n = 2
18 citations from 17 
studies included in 
qualitative synthesis
Figure 1 Selection of studies.
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Page 3 of 11Table 1 Study characteristics and mortality rates according to smoking status at index event
Study Paradox? Time
symptoms to
inclusion
Publ. Enroll. Index
Event
n Current
(C)
n (age)
Former
(F)
n (age)
Never (N)
n (age)
Follow
-up
Total mortality Adjusted mortality rates
with 95% confidence
interval
CF N
Randomised clinical trials in STEMI patients (thrombolytic treatment)
GUSTO-1 [13] Yes 3.2 ± 1.65 h 1995 90 to
93
STEMI 40,599 17,507 (55) 11,117
(64)
11,975 (66) 30d 4.0% 6.7% 10.3% OR 1.25 (1.11 to 1.39) N vs. C
Barbash et al. [12] Yes 3.0 ± 1.6 h 1993 88 to
89
STEMI 8,259 3,649 (58) 2,244 (64) 2,366 (67) 6 m 7.7% 12.1% 17.6% OR 1.35 (1.12 to 1.61) N vs. C
+F
GISSI-2 [23] No < 3 h in 70% 1998 88 to
89
STEMI 9,694 5,151 (57) 1,932 (64) 2,611 (68) In-hosp. 4.7% 7.6% 13.8% OR 0.80 (0.60 to 1.07) C vs. N
OR 0.97 (0.70 to 1.35) F vs. N
Randomised clinical trials in STEMI patients (invasive treatment)
CADILLAC [27] No < 12 h 2004 97 to
99
STEMI 2,082 898 (53) 546 (64) 638 (65) 1 y 2.9% 3.7% 6.6% HR 0.96 (0.52 to 1.76) C vs. N
Randomised clinical trials in patients with NSTE-ACS (invasive treatment)
SYNERGY [22,24] No < 24 h 2008 01 to
02
NSTE
-ACS
9,971 2,404 (61) 3,491 (69) 4,076 (70) 1 y 6.5% 9.1% 6.7% HR 1.77 (1.42 to 2.21) C vs. N
Multi-centre post-AMI randomised trials
TRACE [21] No 2 to 6 d 1999 90 to
92
AMI 6,485 3,341 (64) 1,420 (71) 1,724 (74) 3 y 26 to
27%
38 to
39%
42 to
43%
HR 1.04 (0.93 to 1.15) C vs. N
OPTIMAAL [20] No < 10 d 2004 98 to
99
AMI 5,475 1,832 (62) 1,867 (69) 1,776 (71) 2.7 y 16.3% Incl. in
C
19.3% HR 1.08 (0.93 to 1.25) C+F vs.
N
Single-centre observational studies of patients with AMI
Mølstad [25] Yes NA 1991 82 to
84
AMI 484 184 (61) Incl. in N 456 (70) 3 m 11 to
13%
Incl. in
N
32 to
34%
HR 0.62 (0.36 to 1.04) C vs. N
+F
HR 0.55 (0.33 to 0.93) C vs. N
+F
Bettencourt et al.
[14]
No NA 2004 01 to
02
ACS 901 369 (58) Incl. in C 532 (69) In-hosp. 2.6% Incl. in
F
6.6% OR 0.96 (0.38 to 2.41) C+F vs.
N
Gaspar et al. [16] No NA 2009 04 to
07
ACS 1,228 450 (58) Incl. in C 778 (68) 6 m 9.3% Incl. in
C
13.1% OR 1.25 (0.61 to 2.54) C+F vs.
N
Aune et al.
§ [7] No NA 2010 03 to
07
NSTEMI 381 103 (63) Incl. in N 278 (80) 1y 22% Incl. in
N
27% HR 2.61 (1.43 to 4.79) C vs. N
+F
Registries
Gottlieb et al. [17] No NA 1996 94 AMI 999 367 (57) Incl. in N 632 (67) 6 m 7.9% Incl. in
N
21.5% HR 0.84 (0.54 to 1.30) C vs. N
+F
Andrikopoulos et
al.
[11]
No < 24 h 2001 93 to
94
AMI 5507 3,853 (59) Excluded 1,654 (70) In-hosp. 7.4% NA 14.5% RR 1.12 (0.86 to 1.44) C vs. N
NRMI 2 [18] Yes NA 2002 94 to
97
AMI 297,458 72,585 (58) Incl. in N 224,871
(72)
In-hosp. 8.0% Incl. in
N
16.4% OR 0.86 (0.83 to 0.90) C vs. N
+F
ARIAM [26] Yes < 24 h
criterion
2004 95 to
01
AMI 17,761 5,796 (57) 3,494 (67) 8,471 (70) ICU/
CCU
5.0% 9.3% 13.3% OR 0.77 (0.66 to 0.91) C vs. N
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1Table 1 Study characteristics and mortality rates according to smoking status at index event (Continued)
UAP 7,795 1,721 1,950 4,124 ICU/
CCU
0.7% 1.0% 1.5% OR 0.81 (0.48 to 1.36) C vs. N
IBERICA [15] Yes < 12 h in 82% 2007 97 to
98
AMI 7,796 3,057 (56) 1,730 2,839 (65) 28 d 8.9% 16.9% 20.1% OR 0.57 (0.42 to 0.78) C vs. N
GRACE [19] No NA 2005 99 to
02
ACS 19,325 5,276 (57) 5,691 (67) 8,358 (71) In-hosp. 3.3% 4.5% 6.9% OR 1.01 (0.80 to 1.27) C vs. N
ACS, acute coronary syndrome; AMI, acute myocardial infarction; CCU, coronary care unit; HR, hazard ratio; ICU, intensive care unit; OR, odds ratio; NA, not available; NST-ACS, non-ST-segment acute coronary
syndrome; NSTEMI, non-ST-segment elevation myocardial infarction; RR, relative risk; STEMI, ST-segment elevation myocardial infarction; UAP, unstable angina pectoris.
§The adjusted HR is for the conservative
treatment cohort (2003) only. For the invasive cohort (2006) there was no difference in mortality for smokers and non-smokers (data not published).
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1or without abciximab [27]. Although current smokers
had a lower crude mortality rate, the adjusted analysis
did not find a lower mortality than that of non-smokers.
RCT of non-ST-segment elevation acute coronary syndrome
(NSTE-ACS) subjected to invasive management
In the SYNERGY trial [28] patients with NSTE-ACS
were randomised to enoxaparin or unfractionated
heparin and then underwent coronary angiography and
subsequent PCI or coronary artery bypass grafting
(CABG). The crude mortality rate after one year was
similar among smokers and non-smokers [24]. In the
adjusted analysis there was a significant mortality excess
among smokers vs. non-smokers, supporting the unfa-
vourable effect of current smoking at baseline [22].
Multi-centre post-AMI studies from RCTs
The TRAndolapril Cardiac Evaluation (TRACE) study
consisted of 2,606 patients and aimed to determine
whether patients with left ventricular dysfunction post
AMI would benefit from long-term treatment with
trandolapril vs. placebo [29]. In a study of 6,676 conse-
cutive AMI patients screened for participation in the
TRACE study, the long-term mortality was far lower
among smokers than either ex- or non-smokers. In spite
of this, the adjusted analysis did not give any evidence
to support the existence of a smoker’s paradox in this
population [21].
The Optimal Trial In Myocardial Infarction with the
Angiotensin Antagonist Losartan (OPTIMAAL) study
included selected patients with AMI and evidence of
heart failure for randomised treatment with captopril vs.
losartan [20]. The unadjusted mortality rate among cur-
rent smokers was 17% lower than among non-smokers,
but this decreased risk was eliminated after adjustment
for age and other baseline differences.
Single centre observational studies of patients with AMI
Mølstad included 484 unselected AMI patients between
1982 and 1984 [25]. The three-month mortality rate
among current smokers was only one-third of that
among ex- and never-smokers combined. In a “final”
multivariate model, current smoking had a significant
protective effect.
Bettencourt et al. [14] and Gaspar et al. [16] included
consecutive patients with ACS and could not verify the
existence of the smoker’s paradox. In the latter study
the adjusted analysis indicated a higher six-month mor-
tality rate among current and former vs. never-smokers
(Figure 1).
In our own study of 381 unselected NSTEMI patients,
smokers in the conservative treatment cohort had signif-
icantly higher adjusted one-year mortality than non-
smokers (including ex-smokers) [7]. Such an increased
mortality for smokers was not observed in the invasive
cohort (data not published).
Registries
A nationwide prospective survey comprised of patients
admitted with AMI in all coronary care units (CCU)
operating in Israel during a two-month period [17].
Although the six-month mortality rate among smokers
was approximately one-third of that among ex- and
never-smokers combined, the adjusted analysis could
not verify the smoker’s paradox.
Within the Hellenic registry of patients admitted to
hospital with AMI [11] there was also no evidence of
any adjusted in-hospital survival benefit among current
vs. non-smokers.
By far the largest registry in this overview was the
National Registry of Myocardial Infarction 2 (NRMI 2)
[18], with data from 297,458 patients with confirmed
AMI admitted to participating hospitals but without
hospital transfer. Crude in-hospital mortality among
smokers was 50% lower than among the on-average 14
years older non-smokers. A highly significant OR for
Figure 2 Forest plots of adjusted mortality in smokers vs. non-
smokers. Odds ratios (OR)/hazard ratios (HR) with 95% confidence
intervals for death during follow-up for smokers compared with
non-smokers in the studies included. Circles indicate data derived
from randomised trials. Squares indicate data derived from
observational studies or registries. Open symbols indicate
contemporary studies enrolling patients mainly after 2000. Closed
symbols indicate older studies enrolling patients in the pre-
thrombolytic and thrombolytic era. Symbol size reflects the sample
size of the studies and registries. *Inverted OR from original paper.
§The adjusted HR is for the conservative treatment cohort (2003)
only. For the invasive cohort (2006) there was no difference in
mortality for smokers and non-smokers (data not published).
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Page 6 of 11reduced mortality in the adjusted analysis supported the
existence of a “smoker’s paradox”.
The Análisis del Retraso en el Infarcto Agudo de Mio-
cardio (ARIAM) registry from Spain included patients
with AMI and UAP admitted to a CCU/Intensive Care
Unit (ICU) [26]. In patients with AMI, the CCU/ICU
mortality was nearly one-third among smokers when
compared with non-smokers. The adjusted OR for smo-
kers was significantly in favour of the paradox. The
Investigación, Búsqueda Específica y Registro de Isque-
mia Cooronaria Aguda (IBERICA) registry included
patients between 25 and 74 years of age admitted to
hospital with AMI. Within this registry, smokers had a
lower adjusted 28-day mortality rate than the non-smo-
kers used as evidence in favour of the paradox.
The Global Registry of Acute Coronary Events
(GRACE) included patients admitted to hospital with a
diagnosis of ACS. In an analysis of 19,325 patients the
in-hospital mortality rate among smokers was only half
of that among never-smokers (3.3% vs. 6.9%). There was
no significant difference in adjusted OR for current
smokers compared with never-smokers. These results
were consistent in all three subgroups of the ACS popu-
lation studied (STEMI, NSTEMI and unstable angina
pectoris).
Confounding factors included in the adjusted analyses
The confounding variables used in the multivariate ana-
lyses (in addition to smoking status) are presented in
Table 2. The studies include a wide range of covariates
both for baseline risk factors and treatment provided. Four
observational studies did not adjust for any treatment pro-
vided during hospitalisation [14,16,25,26]. Three registries
[15,17,19], in addition to the CADILLAC trial [27],
included invasive treatment in the multivariate analyses.
The NRMI 2 registry adjusted for “any reperfusion ther-
apy” without specifying the proportion of patients under-
going invasive procedures [18]. Only two studies included
renal function in the multivariate analyses [24,25].
Comments
Main findings
The smoker’s paradox was observed in 6 of the 17 stu-
dies included as the basis of this review. One of these
studies was an observational single-centre study enrol-
ling unselected AMI patients between 1982 and 1984
[25]. The five other studies dated from the late 1980s
and early 1990s and included patients according to the
former WHO classification and before the routine use
of invasive revascularisation [12,13,15,18,26].
Possible explanations of the smoker’s paradox
The possible explanations for the reported paradoxical
findings can be categorised as being either due to
systematic errors, residual confounding or different
pathogenesis: the latter, therefore, representing a true
effect of smoking. Systematic errors would include pub-
lication bias. The declining frequency of papers report-
ing the “smoker’s paradox” during the last decade
supports our argument that the paradox was the result
of skewed reports during the 1980s to 1990s. Another
systematic error might be that smokers with an acute
cardiac event could have a greater case fatality before
admission to hospital than non-smokers [15,30,31].
Those admitted alive to the hospital would, therefore,
already represent the survivors. This notion is supported
by the fact that the smoker’s paradox has only been
demonstrated in hospitalised patients.
Adjustment for age and co-morbidity did reduce the
magnitude of the smoking effect in many of the studies,
but not all. Part of the remaining effect could be due to
residual confounding, both because of measurement
errors in the co-factors and lack of information about
relevant risk factors. The six studies supporting a smo-
ker’s paradox have included STEMI patients, with fibri-
nolysis the dominant reperfusion strategy. This may
indicate that there are slight differences in the patho-
genesis of the acute coronary event in smokers as com-
pared to non-smokers. It has previously been shown
that smokers with STEMI have improved myocardial
perfusion after fibrinolysis compared to non-smokers,
despite adjustment for differences in age and co-morbid-
ities [32,33]. Tobacco smoking is also associated with
increased levels of circulating fibrinogen and tissue fac-
tor. This suggests a more fibrin-rich thrombus in smo-
kers with STEMI which would leave them more
amenable to fibrinolytic therapy [34] and thus an
improved survival rate. All these explanations may oper-
ate in unison to contribute to the observation that smo-
kers perform better than non-smoker after an AMI.
Studies favouring the paradox
Randomised trials
The International Tissue Plasminogen Activator/Strep-
tokinase Mortality Trial [12] and GISSI-2 [23] had a
similar design and enrolled STEMI patients within the
same time period.
A “smoker’s paradox” was observed in the Interna-
tional study, whereas only a non-significant trend for
better outcome for smokers was demonstrated in GISSI-
2. These two studies bring forward the problem of the
classification of former smokers. In the International
study the OR for six-month mortality was presented for
never-smokers vs. current + former smokers, whilst the
contrasting GISSI-2 only reported in-hospital mortality
in current vs. never-smokers.
In the GUSTO-1 study, 40,599 patients were included
in an analysis of 30-day mortality in relation to smoking
Aune et al. BMC Medicine 2011, 9:97
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that concept of the smokers paradox is first coined.
Although not stated expressively in the abstract of the
original article, the results from the adjusted analysis
were significantly in favour of the paradox in the overall
population studied. The abstract refers to the adjusted
OR among 2,431 patients subjected to the angiographic
substudy, among which the paradox was not apparent.
Registries
NRMI 2 reports on 297,458 patients (58%) without hos-
pital transfer out of 510,044 included patients from
1994 to 1997 [18]. The findings are clearly in favour of
Table 2 Covariates in addition to smoking status used in the multivariate analyses
Study Baseline and clinical characteristics Reperfusion and medication
Studies supporting the existence of a smoker’s paradox
Mølstad [25] Age, atrial fibrillation, s-creatinine, s-potassium None
Barbash et al.
[12]
Age, sex, MI site, diabetes, previous MI, antecedent angina,
hypertension, hypotension at entry, Killip class, body mass index,
hypercholesterolemia, family history of CAD
Time to lysis
GUSTO-1 [13] Age, sex, systolic blood pressure, Killip class, heart rate, MI site,
previous MI, previous CABG, height, diabetes, hypertension,
cerebrovascular disease
Time to lysis, type of thrombolytic treatment
NRMI 2 [18] Age, sex, MI site, previous MI, previous CABG, weight, diabetes,
hypertension, hypercholesterolemia, family history of CAD, black
race, other race, previous heart failure, previous PTCA, previous
stroke, Q vs. non-Q,
Any reperfusion therapy, aspirin first 24 hours, any heparin,
intravenous nitroglycerine, beta-blocker, i.v. lidocaine, i.v.
magnesium, ACE-inhibitor, calcium channel blocker, other anti-
thrombin, other antiplatelet
ARIAM [26] Age, Killip class, MI site, diabetes, Q-wave, non-Q-wave with ST
elevation, non-Q-wave with ST decent
None
IBERICA [15] Age, sex, MI site, previous MI, diabetes, hypertension, previous
angina, spline function for symptoms monitoring, cardiogenic
shock or acute pulmonary oedema, severe arrhythmias
Thrombolysis, primary angioplasty, aspirin, beta-blocker
Studies not supporting the existence of a smoker’s paradox
Gottlieb et al.
[17]
Age, sex, systolic blood pressure < 100 mmHg, heart rate > 100/
min, Killip class ≥ 2, anterior MI, diabetes, hypertension, previous
MI, previous angina, Q-wave MI, family history of CAD, CHF
during index hospitalization, atrial fibrillation during
hospitalization
Thrombolytic therapy, invasive coronary procedures
GISSI-2 [23] Age, sex, Killip class, MI site, hypertension, diabetes, previous
angina, body mass index, number of leads with ST elevation
Time to lysis
TRACE [21] Age, sex, body mass index, COPD, previous angina, previous MI,
hypertension, family history of CAD, CHF, wall motion index, Q
wave anterior MI
Thrombolytic treatment
Andrikopoulos
et al. [11]
Age, sex, diabetes, hypertension, previous MI Thrombolytic treatment
OPTIMAAL [20] Age, sex, COPD, cerebrovascular accidents, diabetes,
hypercholesterolemia, hypertension, previous MI, Killip Class, Q
wave MI, MI site, peripheral vascular disease
Thrombolytic treatment, discharge medication
Bettencourt et
al. [14]
Age, sex None
GRACE [19] Age, sex, geographical region, previous angina, previous MI,
previous PCI/CABG, hypertension, diabetes, hyperlipidemia,
chronic heart failure, Killip class, blood pressure, heart rate
Thrombolytic treatment, catheterization, PCI, CABG, aspirin, UFH,
LMWH, Glycoprotein IIb/IIIa inhibitor, ACE-inhibitor, calcium
channel blocker, beta-blocker, statin
CADILLAC [27] Age, sex, Killip class ≥ 2, MI site, previous MI, previous CABG,
diabetes, hypertension, hypercholesterolemia, LAD culprit vessel,
triple vessel disease, baseline TIMI 0 or 3
Stent randomization, abciximab randomization, time from MI to
ER, time from ER to first balloon
SYNERGY [24] Age, gender, creatinine clearance, heart rate, history of CHF,
diabetes, baseline rales, ST depression on baseline ECG, weight,
peripheral vascular disease, Killip class 3 or 4, No positive
biomarkers at randomization, T-wave inversion on baseline ECG
Enoxaparin vs. UFH
Gaspar et al.
[16]
Age, left ventricular dysfunction, Killip class > 1, ST-elevation ACS None
Aune et al. [7] Age, s-creatinine, previous left ventricular systolic dysfunction,
interaction term (current smoking/strategy)
Invasive strategy, aspirin, statin
ACE-inhibitor, angiotensin converting enzyme inhibitor; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CHF, congestive heart failure; COPD,
chronic obstructive pulmonary disease; ER, emergency room; LAD, left anterior descending artery; LMWH, low molecular weight heparin; MI, myocardial
infarction; PCI, percutaneous coronary intervention; PTCA, percutaneous transluminal coronary angioplasty; UFH, unfractionated heparin.
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compared with 27 to 28% in the overall NRMI 2 popu-
lation [35]. This indicates that the smokers were more
likely to be transferred to other hospitals and hence
excluded from the analysis. The rather surprising “para-
doxical” protective effects of a family history of CAD,
hypercholesterolemia and various medical treatments
observed in that model were not commented upon by
the authors.
The authors of ARIAM point out that registries in
general may have inherent defects due to the possibility
of unidentified confounders not included in the analyses
[26]. A selection bias may have been present since only
patients admitted to the participating hospitals ICU/
CCU were included. The IBERICA registry is the only
registry supporting the presence of the paradox that
incorporated primary PCI in the multivariate regression
model. In spite of that, only a minority of patients were
subject to such treatment.
The treatment scenario in the late 1980s and early
1990s was quite different from today’s practice.
Although the preferred treatment for STEMI now is pri-
mary PCI, fibrinolysis remains an important alternative
to mechanical revascularisation. In Europe, 5 to 85% of
patients with STEMI undergo primary PCI [36]. Trans-
fer delays may be unacceptably long before primary PCI
is performed, especially for patients living in rural areas
or reporting to non-PCI centres. As opposed to the
thrombolytic era where the paradox was observed,
patients who have had successful thrombolysis should
be referred within 24 hours for angiography and revas-
cularization as required [37]. In none of the studies and
registries supporting the smoker’s paradox was such a
treatment strategy applied.
The single centre study
The strength of Mølstad’s study is the inclusion of con-
secutive, unselected patients [25]. At that time no reper-
fusion modalities were available, and the results are
purely of historic interest. This study demonstrates the
problems related to multivariate analyses of a small
patient population, with results being reliant upon the
nature and number of the covariates put into the model.
When usage of diuretics was added as a fifth covariate
in the multivariate model, there was no longer a signifi-
cant survival benefit for smokers.
Studies not supporting the paradox
Randomised trials
In TRACE some different confounders to those used in
the thrombolytic studies were included, with the study
recruiting screenees for a randomised trial [21]. The
study population that was screened for entry into
TRACE is probably representative of unselected AMI
patients admitted to hospital alive with an AMI. On the
other hand, OPTIMAAL included highly selected
patients with AMI and heart failure [20]. The percen-
tage of patients given fibrinolysis was 54% in OPTI-
MAAL screenees and 39% in TRACE screenees, as
opposed to 100% in the fibrinolytic trials. Such differ-
ences, along with selection criteria, may explain the dif-
ferent conclusions reached by these studies and the
fibrinolytic studies.
In the more recent CADILLAC trial, in which patients
were selected to undergo primary PCI for STEMI, the
paradox could not be verified [27]. This suggests that
the possible existence of a smoker’s paradox does not
extend into the invasive era.
I nS Y N E R G Y ,t h eo n l yr a n d o m i s e dt r i a li n c l u d i n g
NSTE-ACS with patients scheduled for invasive manage-
ment, a significantly increased adjusted HR for one-year
mortality in current vs. never-smokers was found [24].
Registries
Both the Israeli [17] and Hellenic [11] registries
included hospitalised patients with AMI in the fibrinoly-
tic era. Similar to NRMI 2 [18], IBERICA [15] and
ARIAM [26], the mortality rate was compared among
current vs. non-smokers, with the results contradictory.
It is possible that the number of patients was too small
to register the differences noted in the three larger
registries.
The GRACE registry was the only study to include
patients based upon the current definition of ACS and
included in-hospital invasive procedures as a covariate
[19]. Neither in the total population of nearly 20,000
patients, nor in the subgroups of patients with STEMI,
NSTEMI or UAP, could the existence of the paradox be
verified.
Single centre studies
In neither of the two single centre studies from Portugal
[14,16] could the paradox be demonstrated, with one
showing a non-significant increase in odds ratio for cur-
rent vs. non-smokers for six-month mortality [16] (in
keeping with the findings from SYNERGY). In our study
of NSTEMI patients a significant interaction between
treatment strategy (conservative vs. invasive) and smok-
ing at admission was observed implying a statistically
significant effect of smoking on mortality. However, due
to the statistically significant interaction term between
cohort and smoking, the effect of smoking differed
between cohorts. Smokers in the conservative cohort
had a statistically significant higher adjusted mortality
than non-smokers. In this study smokers received a par-
ticular clinical benefit from an early invasive strategy
[7], and there was no statistically significant differences
between mortality for smokers as compared to non-
smokers in the invasive cohort (data not published).
Accordingly, there was no evidence for the existence of
a smoker’s paradox in our study.
Aune et al. BMC Medicine 2011, 9:97
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Page 9 of 11Limitations of the overview
In a systematic search there will always be a conflict
between completeness and accuracy. We tried to per-
form as wide a search as possible and tested the initial
search for possible omissions according to known
important publications. Nevertheless, we cannot exclude
the possibility of having omitted relevant important stu-
dies. In that context, two recent studies that did not
meet our inclusion criteria are of interest. They address
the important smoking interaction of clopidogrel. Desai
et al. presented data from 3,427 STEMI patients [38].
They found that the beneficial effect of clopidogrel was
especially pronounced among those who smoked ≥ 10
cigarettes per day. The other study by Bliden et al.o f
259 patients undergoing elective stenting shows that clo-
pidogrel induced increased platelet inhibition and lower
aggregation as compared with non-smokers [39]. The
design of these studies, however, did not allow for the
exploration of the existence of the “paradox”.
Due to expected variations in the definition of non-
fatal cardiovascular events, as well as the sub-classifica-
tion of fatal events from 1963 onwards, this overview
does not explore possible associations between smoking
status and events other than total mortality. In addition,
the overview does not include any mechanistic studies.
Because of the heterogeneity of the data we did not find
it meaningful to make a formal meta-analysis.
Conclusions
The “smoker’sp a r a d o x ” was predominantly observed in
AMI patients selected according to the WHO criteria of
the 1980s and 1990s. During that time period fibrinoly-
sis was the dominant reperfusion strategy for such
patients. The paradox, however, has not been demon-
strated in more recent studies using routine early inva-
sive management, although, in one recent study smokers
with NSTEMI have been shown to benefit more from an
early invasive strategy than non-smokers. As such, we
would be wise to encourage smoking cessation rather
than relying on the “positive effects” of the so-called
paradox.
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